共 50 条
<bold>To Explore the Mechanism of Maiwei Dihuang Decoction in the Treatment of Non-small Cell Lung Cancer based on Network Pharmacology Combined with LC-MS</bold>
被引:0
|作者:
Jiang, Tao
[1
]
Lu, Yang
[1
]
Yang, Wanzhi
[2
]
Xu, Jinhong
[1
]
Zhu, Mingxing
[1
]
Huang, Yong
[1
]
Bao, Fang
[1
]
Zheng, Shengqi
[1
,3
]
Li, Yongxia
[1
,3
]
机构:
[1] Navy Anqing Hosp, Dept Pharm, Anqing, Anhui, Peoples R China
[2] Anhui Med Univ, Peoples Hosp 1, Dept Pharm, Anqing, Anhui, Peoples R China
[3] Navy Annexing Hosp, Dept Integrated Oncol Tradit Chinese & Western Med, Anqing, Anhui, Peoples R China
关键词:
Network pharmacology;
LC-MS;
molecular docking;
non-small cell lung cancer;
Maiwei Dihuang decoction;
cancer signal pathway;
TRADITIONAL CHINESE MEDICINE;
RADIATION-THERAPY;
HERBAL MEDICINE;
TARGETING STAT3;
SURVIVAL;
CHEMOTHERAPY;
CURCUMIN;
BRAIN;
P53;
D O I:
10.2174/1573409920666230823161355
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Objective: To explore the mechanism of Maiwei Dihuang decoction in the treatment of non-small cell lung cancer (NSCLC) by using network pharmacology and LC-MS technology. Methods The effective components in Maiwei Dihuang decoction were detected by liquid chromatography-mass spectrometry (LC-MS). Use the SuperPred database to collect the relevant targets of the active ingredients of Mai Wei Di Tang, and then collect the relevant targets of non-small cell lung cancer from GeneCards, DisgenNET and OMIM databases. On this basis, PPI network construction, GO enrichment analysis and KEGG pathway annotation analysis were carried out for target sites. Finally, AutoDock Vina is used for molecular docking. Results We further screened 16 effective Chinese herbal compounds through LC-MS combined with ADME level. On this basis, we obtained 77 core targets through protein interaction network analysis. Through GO, KEGG analysis and molecular docking results, we finally screened out the potential targets of Maiwei Dihuang Decoction for NSCLC: TP53, STAT3, MAPK3. Conclusion Maiwei Dihuang decoction may play a role in the treatment of NSCLC by co-regulating TP53/STAT3/MAPK3 signal pathway.
引用
收藏
页码:590 / 597
页数:8
相关论文